STERIS’ (TSE:STE – Free Report) – Equities researchers at Cormark upped their FY2025 earnings estimates for shares of STERIS’ in a research note issued to investors on Thursday, March 13th. Cormark analyst B. Watson now anticipates that the company will post earnings of $0.52 per share for the year, up from their previous estimate of $0.38. Cormark currently has a “Moderate Buy” rating on the stock. Cormark also issued estimates for STERIS’’s FY2026 earnings at $0.61 EPS.
Separately, Atb Cap Markets upgraded shares of STERIS’ to a “strong-buy” rating in a research report on Sunday, December 22nd.
STERIS’ Stock Performance
STERIS’ Company Profile
STERIS’s MISSION IS TO HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science product and service solutions around the globe by providing innovative healthcare and life science product and service solutions around the globe.
Read More
- Five stocks we like better than STERIS’
- Find and Profitably Trade Stocks at 52-Week Lows
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- Where Do I Find 52-Week Highs and Lows?
- 3 Must-Own Stocks to Build Wealth This Decade
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for STERIS’ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS’ and related companies with MarketBeat.com's FREE daily email newsletter.
